DFCM
BCRX icon

Dark Forest Capital Management’s BioCryst Pharmaceuticals BCRX Stock Holding History

Dark Forest Capital Management’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-78,103
Closed -$744K – 807
2026
Q1 		$744K Buy
+78,103
New +$607K 0.07% 453
2025
Q2 		– Sell
-32,464
Closed -$243K – 1189
2025
Q1 		$243K Buy
32,464
+2,771
+9% +$22.4K 0.01% 1113
2024
Q4 		$223K Sell
29,693
-19,683
-40% -$149K 0.03% 783
2024
Q3 		$375K Buy
+49,376
New +$375K 0.05% 510
2022
Q4 		– Sell
-6,732
Closed -$85K – 1150
2022
Q3 		$85K Buy
6,732
+6,694
+17,616% +$86.1K 0.01% 485
2022
Q2 		$0 Buy
+38
New +$392 ﹤0.01% 906
2021
Q3 		– Sell
-1,919
Closed -$30K – 1267
2021
Q2 		$30K Buy
+1,919
New +$26.1K 0.01% 516

Other funds holding BCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Dark Forest Capital Management's BCRX Position: Q2 2026 in Review

Dark Forest Capital Management sold out of BioCryst Pharmaceuticals (BCRX) in Q2 2026, closing a stake of 78,103 shares — an estimated $744K sold.

Dark Forest Capital Management first reported a position in BCRX in Q2 2021 and held it in 7 quarters. The position peaked at $744K in Q1 2026. 318 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

  • Dark Forest Capital Management reported no remaining BioCryst Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Dark Forest Capital Management sold 78,103 BioCryst Pharmaceuticals shares in Q2 2026, an estimated $744K.
  • Dark Forest Capital Management first reported a position in BioCryst Pharmaceuticals in Q2 2021 and held it in 7 quarters.
  • Dark Forest Capital Management's BioCryst Pharmaceuticals position peaked at $744K in Q1 2026.
  • 318 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on Dark Forest Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.